WBHF/CMS/HST/4T-118-2025/ SDI-RT(357_361)/2026/376

Select, Excess (+), Less (-)

Tender Inviting Authority: The Deputy Director of Health Services (E&S), Central Medical Stores.

Name of Work: RE E-TENDER (3RD CALL) FOR PROCUREMENT OF SOME DRUG ITEMS UNDER TABLE-A, FOR TWO YEARS FROM THE DATE OF AOC.

Contract No: HST/4T-118-2025/SDI-RT(357&361)/2026/376 Dated: 09-02-2026

Name of the Bidder/ Bidding Firm / Company :

Sl. No. Item Name Cat. No. Tentative annual requirment (as per Accounting Unit) Accounting Unit Estimated Rate in Rs. P Addition / Deduction Addition / Deduction Values Currency Convertion against each Item Quoted Currency in INR / Other Currency Basic Rate should be as per Clause No. 16. (d), PG: 14 of the NIT in Rs. P GST in % Excise Duty in % Cess in % Any Other Taxes/Duties/Levies in Rs. P Other Taxes 2in Rs. P IIIrd Party i.e DGS&D / RITES etc Inspection Charges @0.34%+Service Tax in Rs. P Less for Cenvat Credit,if any respect of Supplies Under full Excise Duty Category in Rs. P

1 Plasma Derived Factor VIII (500 IU./ 250 IU.) /Vial R20.5 Per IU Excess(+) Full Conversion INR

2 Recombinant Anti Hemophilic Factor VIII 1000 IU./Vial R20.2 Vial Excess(+) Full Conversion INR

3 Recombinant Anti Hemophilic Factor VIII 250 IU./Vial R20.3 Vial Excess(+) Full Conversion INR

100 Important Note: 1. All prospective bidders are requested to quote the rate in BOQ as per Accounting Unit & item specification as mentioned in the Table-A. Wrong Quoting of the rate in BOQ will be dealt with as per penal provisions of the T&C of the Tender. 2. Tendered quantity is just a tentative quantity and should not be treated as final. It may increase or decrease, as per need of the state. Keeping this in mind, the supplier is not allowed to seek termination of the Rate Contract after finishing supply of tendered quantity. 3. Quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 4. The prospective Bidders of the said Tender are requested to make a declaration in Affidavit under Annexure VI(b) in case of sole manufacturer/importer (i.e. proprietary in nature). 5. If the Item(s) under sole manufacturer / importer is (are) Proprietary in nature, quarterly intimation is solicited from the approved Bidders positively regarding the status of their Item(s) Proprietary in nature, otherwise their Item(s) will be blocked in the SMIS.

Total in Figures

Quoted Rate in Figures Select %

Please Enable Macros to View BoQ information

TECHNICAL DATA SHEET

Tender NIT No. : HST/4T-118-2025/SDI-RT(357&361)/2026/376 Dated: 09-02-2026

Tender inviting Authority : The Deputy Director of Health Services (E&S)

Bidder's Name :

Sl. No. Cat. No. Item Name with Specification , as provided in the Tender documents Accounting Unit Drug Item Item Specification, offered by the Bidder with documents Accounting Unit quoted by the Bidder in the BOQ Quoted as Manufacturer/ Importer for the item License No under which the item is endorsed. (BIS No. In case of items having IS Specification) Name of the folder & Page No. in which Drug Endorsement/F-10, submitted, Name of the folder & Page No. in which Market Standing/ Marketing Cetificate, submitted Remarks (page no of supportive Documents for non submission of any documents )

1 R20.5 Plasma Derived Factor VIII (500 IU./ 250 IU.) /Vial Per IU Drug

2 R20.2 Recombinant Anti Hemophilic Factor VIII 1000 IU./Vial Vial Drug

3 R20.3 Recombinant Anti Hemophilic Factor VIII 250 IU./Vial Vial Drug